← Back to Search

Protein

A2 Milk for Lactose Intolerance

N/A
Recruiting
Led By Dennis Savaiano, PhD
Research Sponsored by Purdue University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 18 to 65 years of age inclusive at screening
Agrees to refrain from all other treatments and products used for dairy intolerance (e.g., Lactaid® Dietary Supplements) during study involvement
Must not have
Weighing <16.5 kg and BMI > 35 kg/m2
Currently undergoing chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within the 6 hours following milk dose
Awards & highlights
No Placebo-Only Group

Summary

This trial found that A1 β-casein milk causes more inflammation than A2 β-casein milk, suggesting A2 may be easier to digest.

Who is the study for?
This trial is for adults aged 18-65 who have a history of dairy intolerance and have avoided dairy for at least a month. Participants must be non-smokers, not pregnant or lactating, without recent drug abuse, and free from certain medical conditions like diabetes, heart failure, gastrointestinal surgeries that affect digestion, or any immune disorders.
What is being tested?
The study tests whether milk containing A1 beta-casein increases inflammation compared to milk with only A2 beta-casein in people with dairy intolerance. It's a controlled experiment where participants are randomly assigned to receive one type of milk without knowing which one it is (double-blinded).
What are the potential side effects?
Potential side effects may include symptoms typically associated with lactose intolerance such as gas, bloating, cramps, stomach pain and diarrhea. There might also be an increase in inflammatory markers specific to individuals sensitive to A1 beta-casein.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.
Select...
I agree not to use any treatments or products for dairy intolerance during the study.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I weigh less than 16.5 kg and my BMI is over 35.
Select...
I am currently receiving chemotherapy.
Select...
I have been diagnosed with congestive heart failure.
Select...
I do not have HIV, Hepatitis B, or Hepatitis C.
Select...
I have active ulcers or a history of severe ulcers.
Select...
I regularly use antacids or proton pump inhibitors.
Select...
I have diabetes (type 1 or type 2).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within the 6 hours following milk dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and within the 6 hours following milk dose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Difference in hydrogen between commercial and A2 milk
Difference in inflammation between commercial and A2 milk
Difference in symptoms between commercial and A2 milk

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Purdue UniversityLead Sponsor
233 Previous Clinical Trials
71,338 Total Patients Enrolled
3 Trials studying Lactose Intolerance
80 Patients Enrolled for Lactose Intolerance
Dennis Savaiano, PhDPrincipal InvestigatorPurdue University
4 Previous Clinical Trials
928 Total Patients Enrolled
3 Trials studying Lactose Intolerance
80 Patients Enrolled for Lactose Intolerance

Media Library

A1 beta-casein containing milk (Protein) Clinical Trial Eligibility Overview. Trial Name: NCT05660278 — N/A
A1 beta-casein containing milk (Protein) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05660278 — N/A
Lactose Intolerance Research Study Groups:
Lactose Intolerance Clinical Trial 2023: A1 beta-casein containing milk Highlights & Side Effects. Trial Name: NCT05660278 — N/A
~9 spots leftby Dec 2025